Sharaf B, Albatsh T, Khater S, Alrabie R, et al. Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study. Breast Cancer (Dove Med Press) 2026;18:636314.
PMID: 42812550